More than 10 years into this bull market, Buy and Outperform analyst ratings generally come with implied upside potential of 8% to 10%. However, the author of today’s article notes that “One area of the market that can see much greater upside opportunities, which also implies a greater risk, is the biotech and emerging pharmaceutical stocks” – and he proceeds to highlight 20 biotech and pharma stocks that have seen analyst calls since January 1st that suggest much larger upside potential. For more, CLICK HERE.
As analysts unveil their top stock picks for 2020, it’s also worth examining how their top picks for 2019 ended up performing. Today’s article does just that, identifying the top 20 Wall Street picks for 2019 among large-cap, mid-cap and small-cap stocks (based on the number of “buy” or equivalent analyst ratings and implied upside potential at the beginning of the year) and their total returns through mid-December. How did analysts’ stock selections do – and how does this analysis “shed light on one of the problems with Wall Street”? CLICK HERE.
While most stocks currently receiving new Buy or Outperform analyst ratings have upside potential of 8% to 10%, the author of today’s article reminds the reader that “There is another type of Buy rating that is far more speculative, one in which the projected upside can be 50%, 100% or exponentially higher.” He proceeds to highlight five biotech stocks that currently fall into this category – with upside potential ranging from 100% to 400%. For these five biotechs – as well as a couple of runners-up with under-100% (but still high) upside potential – CLICK HERE.